A putative class of Intra-Cellular Therapies Inc. investors on Friday in New York federal court accused the biopharmaceutical company of concealing safety concerns about its new schizophrenia medication lumateperone, saying that stock prices dropped after the U.S. Food and Drug Administration questioned the drug's effect on animals.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Direct access to case information and documents.
All significant new filings across U.S. federal district courts, updated hourly on business days.
Full-text searches on all patent complaints in federal courts.